An Oncology Hospital at Home Model of Acute Care Shows Promise
Innovative model of oncology care may reduce unplanned healthcare utilisation and costs in cancer care delivery
Oncology News
ESMO oncology news aims to keep you up to date with the developments that affect you and your daily practice.
Make sure you check these pages frequently, or sign up to our newsletter! To sign up for ESMO newsletters, create a myESMO account here and select the newsletters you’d like to receive.
1549 results
Immune Checkpoint Inhibitor Induced Thyroiditis Associated with a Large Reduction in Death
In a large analysis, the association between thyroiditis and overall survival varied by tumour type, but was strongest in patients with lung cancer
BRAF Inhibitor and Rituximab for the Management of Refractory or Relapsed HCL
A chemotherapy-free regimen of vemurafenib and rituximab induced a durable complete response in most patients with refractory or relapsed hairy-cell leukaemia
Weak Immunogenicity in Patients with Cancer After First Dose of mRNA-based COVID-19 Vaccine
No seroconversion found upon a single dose in elderly cancer patients and those treated with chemotherapy, a reason for not extending the period between the two injections
Maintenance Rucaparib for Platinum-Sensitive Pancreatic Adenocarcinoma with HRD-Associated Mutations
Results of a phase II study in patients with germline or somatic pathogenic variants in BRCA1/2 or PALB2
EMA Recommends Extension of Indications for Venetoclax
New indication concerns combination treatment with a hypomethylating agent in adult patients with newly diagnosed AML who are ineligible for intensive chemotherapy
Cemiplimab Outperforms Investigator’s Choice Chemotherapy in the Second-Line Setting for Recurrent/Metastatic Cervical Carcinoma
The EMPOWER-Cervical 1/GOG-3016/ENGOT-cx9 study met the primary endpoint of overall survival
Activity of Targeted/Immune Therapy Approach in Patients with Advanced Urothelial Cancer
Findings from the BISCAY study
FDA Grants Accelerated Approval to Pembrolizumab for HER2-positive Gastric Cancer
Approval is based on findings from prespecified interim analysis of ongoing KEYNOTE-811 study
Most Cases of Venous Thromboembolic Events, Elevated Aminotransferases, and Interstitial Lung Disease Are Manageable in Patients Receiving Adjuvant Abemaciclib for Early Breast Cancer
Adverse events associated with abemaciclib were characterised in patients participating in the phase III open-label monarchE study
Occurrence of Interstitial Lung Disease Related to Trastuzumab Deruxtecan in Patients with HER2-positive Metastatic Breast Cancer
Close monitoring needed to allow earlier identification and effective management of interstitial lung disease
Identification of Potential Biomarkers for Clinical Benefit Following Dual Neoadjuvant Anti-HER2 Blockade in HER2-positive/HR-negative Early Breast Cancer
Translational findings from the WSG-ADAPT study